Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 10, 2016 8:13 PM ET


Company Overview of Teva Pharmaceuticals USA, Inc.

Company Overview

Teva Pharmaceuticals USA, Inc. manufactures and markets generic drugs in the United States. It offers generic products for various therapeutic options, such as cardiovascular, anti-infective, central nervous system, anti-inflammatory, oncolytic, anti-diabetic, analgesic, dermatologic, respiratory, and women’s health. The company offers its products in various dosage forms, such as tablets, capsules, injectables, creams, ointments, inhalants, solutions, and suspensions. It serves patients through distributors. Teva Pharmaceuticals USA, Inc. was formerly known as Lemmon Pharmacal Company and changed its name to Teva Pharmaceuticals USA, Inc. in 1996. The company was founded in 1945 and is base...

1090 Horsham Road

North Wales, PA 19454

United States

Founded in 1945





Key Executives for Teva Pharmaceuticals USA, Inc.

Chief Executive Officer of Teva North America and President of Teva North America
Age: 67
Vice President of Government Affairs
Vice President of Government Affairs
Vice President of Government Affairs
Vice President of Government Affairs
Compensation as of Fiscal Year 2015.

Teva Pharmaceuticals USA, Inc. Key Developments

United Therapeutics Corporation and Teva Pharmaceuticals USA, Inc. Enter into Settlement Agreement to Settle Ongoing Litigation Concerning Certain Patents Relating to Remodulin (treprostinil) Injection (Remodulin) and Teva's Abbreviated New Drug Application

On January 15, 2016, United Therapeutics Corporation and Teva Pharmaceuticals USA Inc. entered into a settlement agreement to settle their ongoing litigation concerning certain patents relating to Remodulin (treprostinil) Injection (Remodulin) and Teva's Abbreviated New Drug Application (ANDA) seeking approval by the U.S. Food and Drug Administration (FDA) to market a generic version of Remodulin. The settlement agreement relates to a lawsuit filed by the Company against Teva alleging infringement of U.S. Patent Nos. 6,765,117, 7,999,007, 8,497,393, 8,653,137 and 8,658,694. This action is described in further detail in Part II, Item 1 of the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, filed with the U.S. Securities and Exchange Commission (SEC) on October 27, 2015. Under the settlement agreement, the company grants Teva a non-exclusive license beginning on December 23, 2018 to manufacture and commercialize in the United States the generic version of Remodulin described in Teva's ANDA filing, although Teva may be permitted to enter the market earlier under certain circumstances. The Settlement Agreement does not grant Teva a license to manufacture a generic version of any other Company product, such as Tyvaso (treprostinil) Inhalation Solution or Orenitram (treprostinil) Extended-Release Tablets, nor does it grant any rights with respect to any technology associated with the Remodulin Implantable System being developed by the Company and Medtronic Inc., or the pre-filled semi-disposable pump system being developed by the Company and DEKA Research & Development Corp. The Settlement Agreement does not grant Teva any rights other than those required to launch Teva's generic version of Remodulin. In accordance with the terms of the settlement agreement, the parties will submit the Settlement Agreement to the U.S. Federal Trade Commission and the U.S. Department of Justice for review. They will also take certain procedural steps to terminate the outstanding lawsuit.

U.S. District Court Rules in Favor of Helsinn Healthcare S.A. in Lawsuit Filed Against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd

Eisai Co. Ltd. announced that the U.S. District Court for the District of New Jersey has ruled in favor of Helsinn Healthcare S.A. in the patent infringement lawsuit for antiemetic agent ALOXI (palonosetron hydrochloride) brought by Helsinn together with Roche Palo Alto LLC (Roche) against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd. (collectively 'Teva') in the United States, where it was determined that certain formulation patent claims for ALOXI are valid and infringed. In this decision which concerns Teva, the court ruled that the patent claims at issue are valid and are infringed. The term of these formulation patent rights plus pediatric exclusivity currently provides coverage for ALOXI through to July 30, 2024, subject to any appeal.

Teva Pharmaceuticals USA, Inc. Presents at BioNetwork Partnering Summit, Oct-26-2015 09:00 AM

Teva Pharmaceuticals USA, Inc. Presents at BioNetwork Partnering Summit, Oct-26-2015 09:00 AM. Venue: The Ritz-Carlton, Laguna Niguel, California, United States. Speakers: Michael Bayewitch, Director, Search & Evaluation, Biologics.

Similar Private Companies By Industry

Company Name Region
Bracco U.S.A., Inc. United States
Melaleuca, Inc. United States
Nutratech, Inc. United States
MediQuest Therapeutics, Inc. United States
Tensha Therapeutics, Inc. United States

Recent Private Companies Transactions

March 5, 2015
Teva Pharmaceuticals, Abbreviated New Drug Application for Flecainide Acetate

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Teva Pharmaceuticals USA, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at